Hypertension

Last updated: April 18, 2022
Sponsor: Alnylam Pharmaceuticals
Overall Status: Active - Recruiting

Phase

2

Condition

High Blood Pressure (Hypertension)

Treatment

N/A

Clinical Study ID

TX290670
ALN-AGT01-002
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 to 75 years
  • Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication

Exclusion

Exclusion Criteria:

  • Secondary hypertension, orthostatic hypotension
  • Received an investigational agent within the last 30 days
  • Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
  • History of any cardiovascular event within 6 months prior to randomization
  • History of intolerance to SC injection(s)

Study Design

Study Start date:
January 14, 2022
Estimated Completion Date:

Study Description

  • Condition: Hypertension
  • Clinical Trial Identifier: NCT04936035
  • Sponsor: Alnylam Pharmaceuticals

Looking for participants within a 30 mile radius of the study site.

Connect with a study center

  • Clinical Research of South Florida

    Coral Gables, Florida 33134
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.